Rxrx stock forecast.

Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. Now trading above that level — and up in five of the last six ...All 39 ARKG ETF Holdings. The portfolio of Cathie Wood updated daily. These are the positions, trades, and weight of all companies in her ARKG Genomic Revolution ETF. Search tickers or categories... Trader's Guide 2024 Ships December 21st.Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.Recursion Pharmaceuticals (RXRX) stock price prediction is 10.137756245264 USD. The Recursion Pharmaceuticals stock forecast is 10.137756245264 USD for 2024 December 02, Monday; and 517.401 USD for 2028 December 02, Saturday with technical analysis.

Average. $15.57. Current Price. $7.39. Options. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...The 23andMe Holding Co. stock forecast for tomorrow is $ 0.786773, which would represent a -1.46% loss compared to the current price. In the next week, the price of ME is expected to decrease by -7.39% and hit $ 0.739421. As far as the long-term 23andMe Holding Co. stock forecast is concerned, here’s what our predictions are currently suggesting.

Get the latest stock price for Recursion Pharmaceuticals Inc. (RXRX:US), plus the latest news, recent trades, charting, insider activity, ...Recursion's shares have rallied 191.5% in the past three months compared with the industry ’s 0.1% growth. The steep rise in the stock price can also be attributed to RXRX’s recent ...

gguy44. Recursion Pharmaceuticals ( NASDAQ: RXRX) is up 17% on Wednesday in much higher than usual volume as it may be in a short squeeze situation. As of 1215p ET, volume was ~16.6M shares ...Recursion Pharmaceuticals shares have jumped some 80% on Wednesday. The biotech company said that Nvidia is investing $50 million to boost Recursion’s drug-discovery companies. Recursion’s ...3 авг. 2023 г. ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August ... TWLO: Twilio Stock Analysis and Prediction. Financial Depth•800 views.13 июл. 2023 г. ... #price and rxrx stock #chart. Furthermore it explains you the rxrx stock #forecast and how to do rxrx stock prediction. It will also help ...

About the Recursion Pharmaceuticals, Inc. Class A Common Stock stock forecast. As of 2023 December 02, Saturday current price of RXRX stock is 6.910$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Recursion Pharmaceuticals stock price has been showing a declining tendency so we …

(See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Stock Price Forecast. The 7 analysts offering 12-month price forecasts for Recursion Pharmaceuticals Inc have a median target of 14.00, with a high estimate of 35.00 and a low estimate of 9.00 ... What's going on at Recursion Pharmaceuticals (NASDAQ:RXRX)? Read today's RXRX news from trusted media outlets at MarketBeat. Skip to main content. S&P 500 4,594.63 (+0.59%) DOW 36,245.50 (+0.82%) ... Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …Oct 11, 2023 · On the bottom line, Recursion's net loss per share of $0.38 remained flat compared to the prior-year quarter. The company ended the period with $405.9 million in cash and equivalents, which does ... The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months.Industry. Biotechnology. No executives to display. Corporate headquarters. --, --. Find real-time RXRX - Recursion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN ... Currently, Wall Street analysts expect the stock to reach $16.00 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $6.11 at the most recent close of the market. An investor can expect a potential return of 161.87% based on the average RXRX price forecast.

60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ...60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.According to 9 stock analysts, the average 12-month stock price forecast for HP Inc. stock is $31.56, which predicts an increase of 8.57%. The lowest target is $23 and the highest is $39. On average, analysts rate HP Inc. stock as a buy.As of Monday, August 07, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 11.05%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.

Forecast for Fri 01 Sep 2023 price 7.05 RECURSION PHARMACEUTICALS INC stock price forecast for further price development up to 32.48% (time horizon: 1 day) and price target of 7.01 USD. Short-term (time horizon: 2 weeks) RECURSION PHARMACEUTICALS INC share price prediction for 2023-09-01 with daily closed price …Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...

According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and the highest is $33. On average, analysts rate RXRX stock stock as a buy.In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.Nov 28, 2023 · The Baudax Bio Inc stock price gained 31.73% on the last trading day (Friday, 24th Nov 2023), rising from $0.0646 to $0.0851. During the last trading day the stock fluctuated 41.83% from a day low at $0.0600 to a day high of $0.0851. The price has fallen in 6 of the last 10 days and is down by -54.02% for this period. Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price.Price/Earnings Ratio is a widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Actual EPS (Earnings Per Share). data ...Nov 30, 2023 · Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price. (See RXRX stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ...

Before the stock market opened, RXRX stock had catapulted more than 130%. Nvidia stock rose 3.5% to 439.02. Recursion has a searchable data set spanning biology and chemistry. The company says its ...

Ticker Symbol: RXRX: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $18.00: CIK Code: 0001601830: CUSIP Number: 75629V104 ...In the last three months, insiders have sold 333,493 shares of company stock worth $2,375,196. 19.96% of the stock is currently owned by insiders. Wall Street Analysts Forecast GrowthDec 1, 2023 · The Xerox Corporation stock price gained 1.29% on the last trading day (Friday, 1st Dec 2023), rising from $13.99 to $14.17. During the last trading day the stock fluctuated 4.56% from a day low at $13.60 to a day high of $14.22. The price has risen in 6 of the last 10 days and is up by 4.34% over the past 2 weeks. Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ...Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence …One thing we could say about the analysts on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory ...In particular, both Ginkgo Bioworks (NYSE: DNA) and Recursion Pharmaceuticals (NASDAQ: RXRX) are already implementing AI, and in the long term, it could be a crucial factor in their success.Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

Recursion Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales ... Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...Instagram:https://instagram. tsm cbest otc brokergerald johnson gm salaryibm stock dividends Nov 13, 2023 · Future criteria checks 0/6. Recursion Pharmaceuticals's revenue and earnings are forecast to decline at 2.9% and 12.8% per annum respectively. EPS is expected to decline by 9% per annum. Return on equity is forecast to be -471.6% in 3 years. iphone q4teclstock 4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Always seek sound financial advice from your consultant or financial advisor before investing in the stock market. I am a grapefruit, and the stock market is a casino. Disclosure: No positions current in this stock, planning to go Long, likely for between 100 to 500 shares. best technology mutual fund Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.T2 Biosystems, Inc. Common Stock. $0.2229 +0.002 +0.91%. Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended ...